Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

NCT00975637 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: 70 mg SC
DRUG: 210 mg SC
DRUG: 140 mg SC
DRUG: 280 mg SC
DRUG: Placebo

Sponsor

Bausch Health Americas, Inc.